Scholar Rock to Announce Second Quarter 2020 Financial Results and Introduce Newest Members of Management August 7, 2020

On August 3, 2020 Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported that it will host a live conference call and webcast at 8:00am ET on Friday, August 7, 2020 to discuss second quarter 2020 financial results and business progress, as well as provide an introduction to the newest members of its management team (Press release, Scholar Rock, AUG 3, 2020, View Source [SID1234562717]). Participating on the call will be Tony Kingsley (President and CEO), Ted Myles (CFO and Head of Business Operations), and Yung Chyung (Chief Medical Officer).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast
To access the live conference call, please dial 833-519-1308 (domestic) or 914-800-3874 (international), and refer to conference ID 5627485. A webcast of the call will also be available on the Investors & Media section of the Scholar Rock website at View Source An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.

Spectrum Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Corporate Update

On August 3, 2020 Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, reported it will host a conference call to discuss the second quarter 2020 financial results and provide a corporate update on Monday, August 10, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific (Press release, Spectrum Pharmaceuticals, AUG 3, 2020, View Source [SID1234562682]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast:

Monday, August 10, 2020 @ 4:30 p.m. Eastern/1:30 p.m. Pacific
Domestic:

(877) 837-3910, Conference ID# 4093736

International:

(973) 796-5077, Conference ID# 4093736

The conference call will also be available from the Investor Relations section of the company’s website at View Source and will be archived there shortly after the live event.

Veracyte Announces Proposed Public Offering of Common Stock

On August 3, 2020 Veracyte, Inc. (Nasdaq: VCYT) (the "Company") reported that it has commenced an underwritten public offering of 6,000,000 shares of its common stock (Press release, Veracyte, AUG 3, 2020, View Source [SID1234562701]). All of the shares are being offered by Veracyte. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to 900,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Veracyte intends to use the net proceeds from the offering for working capital and other general corporate purposes. The Company may also use a portion of the net proceeds from the offering to acquire or invest in complementary businesses, technologies or other assets, although it has no present commitments or agreements to do so.

Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint lead book-running managers for the offering, William Blair & Company, L.L.C. is acting as a book-running manager and BTIG, LLC, Needham & Company, LLC, and Lake Street Capital Markets, LLC are acting as co-managers.

The shares will be issued pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on May 2, 2019. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by email at [email protected], or by telephone at (866) 471-2526; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 01220, by email at [email protected], or by telephone at (800) 808-7525, ext. 6218.

Sirtex Medical Launches State-of-the-Art SIROS™ System for Advanced SIR-Spheres® Resin Microspheres Delivery

On August 3, 2020 Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, reported the launch of SIROS, an innovative system for the delivery of SIR-Spheres Y-90 resin microspheres (Press release, Sirtex Medical, AUG 3, 2020, View Source [SID1234562719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SIROS offers a visual, intuitive and versatile option for interventional radiologists to deliver SIR-Spheres to patients with liver cancer. With the system’s visually controlled administration, physicians can determine and adjust the precise quantity and speed of SIR-Spheres microspheres delivery. Additionally, the system is designed to be simple to use yet versatile enough to allow expanded options for patient-tailored delivery.

SIROS’ intuitive design features a peel-and-place tubing set, a proprietary needleless D-Vial specifically designed to suspend SIR-Spheres into a vortex that may allow for a more even distribution, and a locking cover to safely secure the microspheres during delivery. A three-step setup further provides quick and simple administration and disposal.

"SIROS brings world-class expertise and innovation together to provide interventional radiologists with the support and technology they need to treat patients with liver cancer," said Kevin R. Smith, Chief Executive Officer of Sirtex. "As established leaders in the industry for more than 20 years, we are pleased to add SIROS to our expanding portfolio of technology designed to advance patient care."

HOOKIPA Announces Issuance of US and European Patents

On August 3, 2020 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers, reported that both the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have issued patents covering HOOKIPA’s proprietary replicating arenavirus technology (TheraT) (Press release, Hookipa Pharma, AUG 3, 2020, View Source [SID1234562683]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patents (US Patent No. 10,722,564 and European Patent No. 3218504) are granted to the University of Geneva. HOOKIPA has exclusively licensed these patents from the University. The patent claims cover current product candidates based on HOOKIPA’s replicating arenavirus platform technology (TheraT), including the Company’s lead oncology product candidates HB-201 and HB-202. These programs are currently in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers.

In addition to the replicating arenavirus platform patents, the USPTO recently granted a patent (US Patent No. 10,669,315) specifically related to HOOKIPA’s HB-201 and HB-202 product candidates, which are two different replicating arenavirus-based vectors encoding the same E7/E6 fusion protein. The patent protection for HB-201 and HB-202 conferred by these platform and product-specific patents extends to 2037 in the United States and 2035 in Europe (not taking into account potential Patent Term Extension or Supplementary Protection Certificates).

"The newly issued patents provide general, long-term patent protection for our arenavirus technology and related oncology programs. The combination of broad patents on our arenavirus platform and specific patents on product candidates underpin the commercial potential of the therapies we are developing," said Joern Aldag, HOOKIPA’s Chief Executive Officer.

About Replicating Arenavirus Technology (TheraT)
HOOKIPA’s proprietary and patented replicating arenavirus technology induces powerful immune responses. HOOKIPA’s replicating arenavirus constructs are engineered to be specific for antigens of choice. Arenaviruses have a natural ability to evade neutralization, enabling repeated intravenous delivery.

The replicating arenavirus platform is able to direct more than 50% of a mouse’s T cells to focus on a single target of choice. In various animal models, immunization with HOOKIPA’s replicating arenavirus resulted in elimination of a primary tumor and metastasis and provided long-term protection against a cancer re-challenge months after primary treatment. The Company believes that its arenavirus-based treatments are more potent immunotherapies than alternative therapeutic modalities.

HOOKIPA’s lead oncology programs, HB-201 and HB-202 for the treatment of Hum Papillomavirus 16-positive cancers, are both based on its replicating arenavirus platform.